# Jae Yong Cho

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2838562/publications.pdf

Version: 2024-02-01

| 61 | 6,598 | 147786 | 144002 |
|---|---|---|---|
| papers | citations | 31 h-index | 57 g-index |

| 61 | 61 | 61 | 8722 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471. | 13.7 | 1,749 |
| 2 | Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, The, 2012, 379, 315-321. | 13.7 | 1,422 |
| 3 | Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449. | 7.0 | 342 |
| 4 | Gene Expression Signatureâ€“Based Prognostic Risk Score in Gastric Cancer. Clinical Cancer Research, 2011, 17, 1850-1857. | 7.0 | 285 |
| 5 | Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. Journal of Clinical Oncology, 2015, 33, 3858-3865. | 1.6 | 248 |
| 6 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nature Communications, 2018, 9, 1777. | 12.8 | 245 |
| 7 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Journal of Cancer Research and Clinical Oncology, 2014, 140, 319-328. | 2.5 | 160 |
| 8 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 2020, 23, 510-519. | 5.3 | 155 |
| 9 | Prognostic Biomarkers for Esophageal Adenocarcinoma Identified by Analysis of Tumor Transcriptome. PLoS ONE, 2010, 5, e15074. | 2.5 | 122 |
| 10 | Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Cancer Research, 2017, 23, 5671-5678. | 7.0 | 121 |
| 11 | Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer. PLoS ONE, 2011, 6, e24662. | 2.5 | 105 |
| 12 | Capecitabine combined with gemcitabine (CapGem) as firstâ€line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 2005, 104, 2753-2758. | 4.1 | 98 |
| 13 | Clinicopathologic Implications of the BRAF<sup>V600E</sup> Mutation in Papillary Thyroid Cancer: A Subgroup Analysis of 3130 Cases in a Single Center. Thyroid, 2013, 23, 1423-1430. | 4.5 | 97 |
| 14 | AMPKÎ± Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Cancer Research, 2012, 72, 2512-2521. | 0.9 | 91 |
| 15 | Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World Journal of Gastroenterology, 2012, 18, 4037. | 3.3 | 76 |
| 16 | Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235. | 7.1 | 74 |
| 17 | Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Therapy, 2002, 9, 725-736. | 4.6 | 71 |
| 18 | Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer. Oncology, 2012, 83, 292-299. | 1.9 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. World Journal of Gastroenterology, 2013, 19, 7078. | 3.3 | 66 |
| 20 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958. | 5.3 | 61 |
| 21 | Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience. Yonsei Medical Journal, 2012, 53, 352. | 2.2 | 60 |
| 22 | Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. Journal of Gastric Cancer, 2017, 17, 132. | 2.5 | 54 |
| 23 | Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer. Journal of Gastric Cancer, 2013, 13, 129. | 2.5 | 53 |
| 24 | Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. World Journal of Gastroenterology, 2012, 18, 5581. | 3.3 | 52 |
| 25 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 143-153. | 5.3 | 45 |
| 26 | Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14â€01). Cancer, 2017, 123, 1958-1964. | 4.1 | 44 |
| 27 | Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Research and Treatment, 2015, 47, 697-705. | 3.0 | 43 |
| 28 | Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235. | 7.0 | 40 |
| 29 | Overexpression of Endoplasmic Reticulum Oxidoreductin 1-Î± (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer. Cancer Research and Treatment, 2016, 48, 1196-1209. | 3.0 | 37 |
| 30 | Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. Experimental and Molecular Medicine, 2011, 43, 341. | 7.7 | 36 |
| 31 | Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 581-589. | 2.8 | 35 |
| 32 | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. Gastric Cancer, 2016, 19, 1095-1103. | 5.3 | 33 |
| 33 | Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. World Journal of Surgical Oncology, 2007, 5, 86. | 1.9 | 31 |
| 34 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain. Oncology, 1996, 53, 192-197. | 1.9 | 30 |
| 35 | Outcome of Adjuvant Therapy for Gallbladder Cancer. Oncology, 2010, 79, 168-173. | 1.9 | 30 |
| 36 | A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. Gastric Cancer, 2019, 22, 1206-1214. | 5.3 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group. Journal of Thoracic Oncology, 2009, 4, 1136-1143. | 1.1 | 25 |
| 38 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer, 2018, 21, 819-830. | 5.3 | 24 |
| 39 | Docetaxel-Induced Onycholysis: The Role of Subungual Hemorrhage and Suppuration. Yonsei Medical Journal, 2007, 48, 124. | 2.2 | 22 |
| 40 | Targeted therapy in gastric cancer: Personalizing cancer treatment based on patient genome. World Journal of Gastroenterology, 2014, 20, 2042. | 3.3 | 22 |
| 41 | Relationship between p53 Overexpression and Gastric Cancer Progression. Oncology, 1997, 54, 166-170. | 1.9 | 19 |
| 42 | Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2009, 64, 317-325. | 2.3 | 18 |
| 43 | Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study. Journal of Thoracic Disease, 2018, 10, 2279-2287. | 1.4 | 18 |
| 44 | Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS ONE, 2017, 12, e0186362. | 2.5 | 15 |
| 45 | Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer. Cancer Research and Treatment, 2011, 43, 236-243. | 3.0 | 15 |
| 46 | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2008, 62, 763-768. | 2.3 | 13 |
| 47 | Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World Journal of Gastroenterology, 2017, 23, 7407-7414. | 3.3 | 13 |
| 48 | Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. Viruses, 2021, 13, 2295. | 3.3 | 13 |
| 49 | Retrospective Comparison of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Modified FAM) Combination Chemotherapy Versus Palliative Therapy in Treatment of Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 484-489. | 1.3 | 12 |
| 50 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Anti-Cancer Drugs, 2008, 19, 631-635. | 1.4 | 10 |
| 51 | 9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 Retinoic acid responsive elements. Cancer Biology and Therapy, 2006, 5, 586-592. | 3.4 | 9 |
| 52 | Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. Cancer Research and Treatment, 2015, 47, 266-273. | 3.0 | 9 |
| 53 | Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer. Cancer Cell International, 2022, 22, 82. | 4.1 | 8 |
| 54 | Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 204-209. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer. Oncology, 2007, 73, 2-8. | 1.9 | 6 |
| 56 | Oxaliplatin Combined with Continuous Infusion of 5-Fluorouracil as First-Line Chemotherapy in Patients with Metastatic or Recurrent Gastric Adenocarcinoma. Chemotherapy, 2009, 55, 200-206. | 1.6 | 6 |
| 57 | Detection of EGFA-SEPT14 fusion in cell-free DNA of a patient with advanced gastric cancer: A case report. World Journal of Clinical Cases, 2021, 9, 2884-2889. | 0.8 | 4 |
| 58 | A Case of Adenocarcinoma Arising within Intra-Abdominal Bronchogenic Cyst. Korean Journal of Medicine, 2012, 82, 374. | 0.3 | 0 |
| 59 | Design of precise third-line therapy for gastric cancer: target or chemotherpy?. Korean Journal of Internal Medicine, 2013, 28, 297. | 1.7 | 0 |
| 60 | A Case of Adenocarcinomatous Transformation of a Sacrococcygeal Teratoma in an Adult. Korean Journal of Medicine, 2013, 85, 101. | 0.3 | 0 |
| 61 | Treatment of a Patient with Kaposi's Sarcoma Arising during Hemodialysis with the Multikinase Inhibitor Pazopanib. Korean Journal of Medicine, 2015, 89, 113. | 0.3 | 0 |